Platelet-activating factor acetylhydrolase: Is it good or bad for you?

Current Opinion in Lipidology

Volumn 15, Issue 3, 2004, Pages 337-341

  Chen, Chu Huang ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Atherosclerosis; Electronegative LDL; Inflammation; Phospholipids

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APAFANT; ENZYME INHIBITOR; RECOMBINANT ENZYME; SB 2443223; UNCLASSIFIED DRUG;

ASTHMA; ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG ACTIVITY; ENZYME ACTIVITY; GENE TRANSFER; HUMAN; LIPID METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; VASCULAR DISEASE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ARTERIOSCLEROSIS; GENE TRANSFER TECHNIQUES; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; OXIDATIVE STRESS;

ANIMALIA;

EID: 2642567931     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200406000-00015     Document Type: Review

References (35)

1. Six DA, Dennis EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 2000; 1488:1-19.
2. Lindbom J, Ljungman AG, Lindahl M, Tagesson C. Increased gene expression of novel cytosolic and secretory phospholipase A(2) types in human airway epithelial cells induced by tumor necrosis factor-alpha and IFN-gamma. J Interferon Cytokine Res 2002; 22:947-955.
3. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374:549-553.
4. Karasawa K, Harada A, Satoh N, et al. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42:93-114. This is an excellent review of PAF-AH isoforms. Its discussion focuses on the biomedical properties of plasma PAF-AH and its role in various disease patterns.
5. Min JH, Jain MK, Wilder C, et al. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry 1999; 38:12935-12942.
6. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003; 40:1-30. This is an elegant review of the physiological and pathological activities of PAF and PAF-like lipids. The thorough discussion on the signaling pathways of these substrates of plasma PAF-AH enhances the understanding of the importance of plasma PAF-AH.
7. 2, is positively associated with increased risk for coronary artery disease and propose possible mechanisms supporting the potential proatherogenic role of this enzyme.
8. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343:1148-1155.
9. Szmitko PE, Wang CH, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003; 108:2041-2048. This review lists plasma PAF-AH as a biomarker for atherosclerosis. It also gives a hypothetical mechanism for this possibility.
10. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003; 44:1381-1386. Plasma PAF-AH activity was found to increase gradually in stable angina and acute coronary syndromes in this recent study. No correlation was found between PAF-AH and other inflammatory markers such as C-reactive protein and fibrinogen.
11. Marathe GK, Silva AR, de Castro Faria Neto HC, et al. Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J Lipid Res 2001; 42:1430-1437.
12. 2 and PPARγ. FEBS Lett 2003; 553:145-150.
13. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Assoc Am Physicians 1992; 105:44-63.
14. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3:57-68.
15. Noto H, Hara M, Karasawa K, et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23:829-835. In this study, the authors demonstrated that transfected human plasma PAF-AH renders murine lipoproteins resistant to oxidative stress and augments the protective effects of HDL in atherogenesis.
16. Marathe GK, Zimmerman GA, McIntyre TM. PAF acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 2002; 278:3937-3947. Paraoxonase-1 has been considered a major phospholipase in HDL and whether enhancement of its activity can increase the protective effect of HDL against oxidized phospholipids has become an important issue. This study addressed this question and the results indicate that plasma PAF-AH is indeed responsible for such activities of HDL.
17. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency: a missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97:2784-2791.
18. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994-→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998; 47:177-181.
19. Balta G, Gurgey A, Kudayarov DK, et al. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb Res 2001; 101:231-234.
20. Subramanian VS, Goyal J, Miwa M, et al. Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma. Biochim Biophys Acta 1999; 1439:95-109.
21. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103:2495-2500.
22. Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J 2000; 14:2032-2039.
23. Miwa M, Miyake T, Yamanaka T, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82:1983-1991.
24. Stafforini DM, Numao T, Tsodikov A, et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest 1999; 103:989-997.
25. Goggel R, Hoffman S, Nusing R, et al. Platelet-activating factor-induced pulmonary edema is partly mediated by prostaglandin E(2), E-prostanoid 3-receptors, and potassium channels. Am J Respir Crit Care Med 2002; 166:657-662.
26. Schuster DP, Metzler M, Opal S, et al. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31:1612-1619. In this prospective, randomized, double-blind, and multicenter trial, recombinant PAF-AH was given intravenously in two different doses to patients without acute respiratory distress syndrome and mortality was compared between the treatment and placebo groups.
27. Biancone L, Cantaluppi V, Del Sorbo L, et al. Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res 2003; 9:4214-4220. Involvement of PAF or PAF-like lipids in malignant tumor growth and the potential therapeutic role of plasma PAF-AH were examined in this interesting study.
28. Marathe GK, Zimmerman GA, Prescott SM, McIntyre TM. Activation of vascular cells by PAF-like lipids in oxidized LDL. Vascul Pharmacol 2002; 38:193-200.
29. Bulger EM, Gourlay D, Cuschieri J, et al. Platelet-activating factor acetylhydrolase inhibits alveolar macrophage activation in vivo. Shock 2003; 20:17-22. The effect of human plasma PAF-AH on macrophage activation was examined in this in-vivo model.
30. Sevanian A, Bittolo-Bon G, Cazzolato G, et al. LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res 1997; 38:419-428.
31. De Castellarnau C, Sánchez-Quesada JL, Benítez S, et al. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20:2281-2287.
32. Chen CH, Jiang T, Yang JH, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003; 107:2102-2108. This recent study showed that a novel highly electronegative and mildly oxidized LDL subfraction, L5, isolated from hypercholesterolemic human plasma can induce marked apoptosis in vascular endothelial cells. Evidence that possible active components of L5 signal through the PAF receptor and are sensitive to degradation by human plasma PAF-AH is demonstrated.
33. Yang CY, Raya JL, Chen HH, et al. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol 2003; 23:1083-1090. This study demonstrated the biochemical and functional characteristics of the novel electronegative LDL subfraction isolated from hypercholesterolemic human plasma.
34. Chen CH, Poucher SM, Henry PD. Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2004; 2:33-43. This is the most recent review on the genetic and functional aspects of fibroblast growth factor 2.
35. Benitez S, Sanchez-Quesada JL, Ribas V, et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 2003; 108:92-96. The association of human plasma PAF-AH with electronegative LDL and nonelectronegative LDL subfractions were compared in this study.